Alpha 2.0
Login Register
» Authors » Atheeshaan Arumuham

Atheeshaan Arumuham

Explore the profile of Atheeshaan Arumuham including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 15
Citations 444
Followers 0
Related Specialties
Psychiatry
Pharmacology
General Medicine
Top 10 Co-Authors
Oliver D Howes
Ellis Chika Onwordi
Matthew M Nour
Eugenii A Rabiner
Ekaterina Shatalina
Mattia Veronese
Sameer Jauhar
Katherine Beck
Thomas Whitehurst
Sridhar Natesan
Published In
Transl Psychiatry
J Psychopharmacol
Lancet Psychiatry
Cell
Healthcare (Basel)
Affiliations
Soon will be listed here.
Recent Articles
1.
The relationship between cortical synaptic terminal density marker SV2A and glutamate early in the course of schizophrenia: a multimodal PET and MRS imaging study
Onwordi E, Whitehurst T, Shatalina E, Carr R, Mansur A, Arumuham A, et al.
Transl Psychiatry . 2025 Mar; 15(1):70. PMID: 40025026
Loss of glutamatergic terminals is hypothesised to contribute to excitation-inhibition imbalance in schizophrenia, supported by evidence that the normal positive association between glutamate concentrations and synaptic terminal density is not...
2.
Mitochondria Make You Think: An [18F]BCPP-EF Positron Emission Tomography Study of Mitochondrial Complex I Levels and Brain Activation during Task Switching
Shatalina E, Whitehurst T, Onwordi E, Whittington A, Mansur A, Arumuham A, et al.
Biol Psychiatry Cogn Neurosci Neuroimaging . 2025 Feb; PMID: 40010687
Background: Mitochondrial complex I is the largest enzyme complex in the respiratory chain and can be non-invasively measured using [18F]BCPP-EF positron emission tomography (PET). Neurological conditions associated with mitochondria complex...
3.
The relationship between SV2A levels, neural activity, and cognitive function in healthy humans: A [11C]UCB-J PET and fMRI study
Shatalina E, Onwordi E, Whitehurst T, Whittington A, Mansur A, Arumuham A, et al.
Imaging Neurosci (Camb) . 2025 Feb; 2:1-16. PMID: 39989611
Synaptic terminal density is thought to influence cognitive function and neural activity, yet its role in cognition has not been explored in healthy humans. We examined these relationships using [11C]UCB-J...
4.
Working memory processes and the histamine-3 receptor in schizophrenia: a [C]MK-8278 PET-fMRI study
Arumuham A, Shatalina E, Nour M, Veronese M, Onwordi E, Kaar S, et al.
Psychopharmacology (Berl) . 2024 Dec; PMID: 39710764
Rationale: Working memory impairment is a prominent feature of schizophrenia which predicts clinical and functional outcomes. Preclinical data suggest histamine-3 receptor (H3R) expression in cortical pyramidal neurons may have a...
5.
Histamine-3 Receptor Availability and Glutamate Levels in the Brain: A PET-1H-MRS Study of Patients With Schizophrenia and Healthy Controls
Arumuham A, Nour M, Veronese M, Beck K, Onwordi E, Lythgoe D, et al.
Int J Neuropsychopharmacol . 2024 Feb; 27(3). PMID: 38373256
Background: The histamine-3 receptor (H3R) may have a role in cognitive processes through its action as a presynaptic heteroreceptor inhibiting the release of glutamate in the brain. To explore this,...
6.
Immune response to vaccination in people with psychotic disorders relative to healthy controls: prospective study of SARS-CoV-2 vaccination
OBrien O, Arumuham A, Mizuno Y, Baxter L, Lobo M, Parmar S, et al.
BJPsych Open . 2024 Feb; 10(2):e49. PMID: 38362901
This prospective study examines the immune response to SARS-CoV-2 vaccination in patients with psychotic disorders compared with healthy volunteers. Participants were recruited naturalistically as part of the UK's COVID-19 vaccination...
7.
Synaptic Terminal Density Early in the Course of Schizophrenia: An In Vivo UCB-J Positron Emission Tomographic Imaging Study of SV2A
Onwordi E, Whitehurst T, Shatalina E, Mansur A, Arumuham A, Osugo M, et al.
Biol Psychiatry . 2023 Jun; 95(7):639-646. PMID: 37330164
Background: The synaptic hypothesis is an influential theory of the pathoetiology of schizophrenia (SCZ), which is supported by the finding that there is lower uptake of the synaptic terminal density...
8.
The histamine system and cognitive function: An in vivo H3 receptor PET imaging study in healthy volunteers and patients with schizophrenia
Arumuham A, Nour M, Veronese M, Onwordi E, Rabiner E, Howes O
J Psychopharmacol . 2023 Jun; 37(10):1011-1022. PMID: 37329185
Background: The histamine-3 receptor (H3R) is an auto- and heteroreceptor that inhibits the release of histamine and other neurotransmitters. Post-mortem evidence has found altered H3R expression in patients with psychotic...
9.
Exploring the mediation of DNA methylation across the epigenome between childhood adversity and First Episode of Psychosis-findings from the EU-GEI study
Alameda L, Liu Z, Sham P, Aas M, Trotta G, Rodriguez V, et al.
Mol Psychiatry . 2023 Apr; 28(5):2095-2106. PMID: 37062770
Studies conducted in psychotic disorders have shown that DNA-methylation (DNAm) is sensitive to the impact of Childhood Adversity (CA). However, whether it mediates the association between CA and psychosis is...
10.
The association between -methyl-d-aspartate receptor availability and glutamate levels: A multi-modal PET-MR brain imaging study in first-episode psychosis and healthy controls
Beck K, Arumuham A, Brugger S, McCutcheon R, Veronese M, Santangelo B, et al.
J Psychopharmacol . 2022 Sep; 36(9):1051-1060. PMID: 36120998
Background: Evidence from post-mortem studies and in vivo imaging studies suggests there may be reduced -methyl-d-aspartate receptor (NMDAR) levels in the hippocampus in patients with schizophrenia. Other studies have reported...